Rhenman & Partners Asset Management’s Medicines Co MDCO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-153,000	Closed	-$7.65M	–	107
2019 Q3	$7.65M	Sell	153,000 -47,000	-24%	-$1.87M	0.96%	43
2019 Q2	$7.29M	Buy	200,000 +70,000	+54%	+$2.29M	0.8%	51
2019 Q1	$3.63M	Sell	130,000 -5,000	-4%	-$118K	0.43%	62
2018 Q4	$2.58M	Hold	135,000	–	–	0.3%	67
2018 Q3	$4.04M	Buy	135,000 +25,000	+23%	+$942K	0.4%	65
2018 Q2	$4.04M	Buy	110,000 +10,000	+10%	+$325K	0.41%	63
2018 Q1	$3.29M	Buy	+100,000	New	+$3.12M	0.41%	62

Other funds holding MDCO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Rhenman & Partners Asset Management's MDCO Position: Q4 2019 in Review

Rhenman & Partners Asset Management sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 153,000 shares — an estimated $7.65M sold.

Rhenman & Partners Asset Management first reported a position in MDCO in Q1 2018 and held it in 7 quarters. The position peaked at $7.65M in Q3 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

Rhenman & Partners Asset Management reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
Rhenman & Partners Asset Management sold 153,000 Medicines Co shares in Q4 2019, an estimated $7.65M.
Rhenman & Partners Asset Management first reported a position in Medicines Co in Q1 2018 and held it in 7 quarters.
Rhenman & Partners Asset Management's Medicines Co position peaked at $7.65M in Q3 2019.
284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.